Ansuategui M, Naharro L, Feria M
Department of Pharmacology, Faculty of Medicine, University of La Laguna, Tenerife, Spain.
Psychopharmacology (Berl). 1989;98(1):93-6. doi: 10.1007/BF00442012.
Although tricyclic antidepressants are especially useful in the treatment of chronic pain conditions, most of the work about its mechanism of action has been made on acute pain tests. The present study was aimed at studying the role played by noradrenergic and opioidergic influences on the antinociceptive activity of subchronically administered clomipramine in the formalin test (a tonic pain model) in rats. Clomipramine produced antinociception after 7 days, administration (2.5 mg/kg/day), an effect equivalent to that obtained by acute morphine (5 mg/kg). The antinociceptive effect of clomipramine was inhibited by the following: nonspecific blocking of alpha 1- and alpha 2-adrenoceptors by phentolamine, specific blocking of alpha 1-adrenoceptors by prazosin; stimulation of alpha 2 receptors by clonidine; and blocking of the opioid receptors by naloxone. Blocking the alpha 2-receptors with yohimbine did not antagonize the effect of clomipramine. These results suggest that clomipramine produces antinociception in this test, partly via the participation of the endogenous opioid system and partly by further activating or potentiating previously activated noradrenergic pathways which are involved in the control of pain information.
尽管三环类抗抑郁药在治疗慢性疼痛状况方面特别有用,但关于其作用机制的大多数研究都是基于急性疼痛试验进行的。本研究旨在探讨去甲肾上腺素能和阿片样物质能影响在大鼠福尔马林试验(一种持续性疼痛模型)中对亚慢性给予氯米帕明的抗伤害感受活性所起的作用。氯米帕明在给药7天(2.5毫克/千克/天)后产生抗伤害感受作用,其效果与急性给予吗啡(5毫克/千克)相当。氯米帕明的抗伤害感受作用受到以下因素的抑制:酚妥拉明对α1和α2肾上腺素能受体的非特异性阻断;哌唑嗪对α1肾上腺素能受体的特异性阻断;可乐定对α2受体的刺激;以及纳洛酮对阿片受体的阻断。育亨宾阻断α2受体并未拮抗氯米帕明的作用。这些结果表明,氯米帕明在该试验中产生抗伤害感受作用,部分是通过内源性阿片系统的参与,部分是通过进一步激活或增强先前已激活的参与疼痛信息控制的去甲肾上腺素能通路。